SEC Form 4 · accession 0001651844-18-000006
NYMOX PHARMACEUTICAL CORP · NYMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James George Robinson
Director
Period of report
Feb 9, 2018
Accepted (ET)
Feb 12, 2018 · 11:00 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001018735
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 9, 2018 | P | 800 | $3.1654 | A | 3,101,350 | D | |
| Common Stock | Feb 9, 2018 | P | 158 | $3.1655 | A | 3,101,508 | D | |
| Common Stock | Feb 9, 2018 | P | 68 | $3.1658 | A | 3,101,576 | D | |
| Common Stock | Feb 9, 2018 | P | 100 | $3.1672 | A | 3,101,676 | D | |
| Common Stock | Feb 9, 2018 | P | 300 | $3.1712 | A | 3,101,976 | D | |
| Common Stock | Feb 9, 2018 | P | 200 | $3.1736 | A | 3,102,176 | D | |
| Common Stock | Feb 9, 2018 | P | 5,374 | $3.1826 | A | 3,107,550 | D |
Table II — derivative securities
No Table II lines on this filing.